SCHEMBL4565359

SCHEMBL4565359

C=CCOC(=O)N1CCC(Nc2cccnc2Cl)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 5/20 0.51
NOS1 P29475 4/20 0.47
SLC6A15 Q9H2J7 1/20 0.46
NOS3 P29474 2/20 0.44
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
RAB9A P51151 2/20 0.41
LMNA P02545 2/20 0.41
CYP2C19 P33261 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 3/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
MAPK14 Q16539 1/20 0.40
KDM4E B2RXH2 3/20 0.39
GPR119 Q8TDV5 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054430 0.87 NOS2 (0.67) NOS2NOS1NOS3ALDH1A1MEN1
Ammonia Solution, Strong SCHEMBL3061153 0.86 NOS2 (0.66) NOS2NOS1NOS3ALDH1A1MEN1
SCHEMBL1285665 0.83 GRIN2B (0.58) NOS2NOS1RAB9ACYP2C19NPC1
SCHEMBL27092752 0.79 POLB (0.63) NOS2ALDH1A1L3MBTL1RAB9AMAPK1
SCHEMBL3063816 0.79 ALDH1A1 (0.46) NOS2NOS1ALDH1A1MEN1KMT2A
Ammonia Solution, Strong SCHEMBL28775699 0.78 ALDH1A1 (0.45) NOS2NOS1ALDH1A1MEN1KMT2A
SCHEMBL4564976 0.76 SLC6A15 (0.44) NOS2NOS1SLC6A15ALDH1A1MEN1
SCHEMBL13319027 0.73 NOS2 (0.67) NOS2NOS1NOS3ALDH1A1MEN1
SCHEMBL28652231 0.73 ALDH1A1 (0.51) NOS2NOS1NOS3ALDH1A1MEN1
SCHEMBL19873872 0.72 ALDH1A1 (0.49) ALDH1A1MEN1KMT2AL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176986-A1 Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate MERCK SHARP & DOHME CORP. 2009-07-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176986-A1 Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate CCKBR, CALCRL, CALCR NOS2 1245/4885NOS1 1282/4885SLC6A15 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.